See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- Vcare Pharm Group reaches commercialization partnership with CTTQ for Eratrectinib
On September 29, 2026, Jiangsu Vcare PharmaTech Co., Ltd. entered into a strategic cooperation agreement with Chia Tai Vican, a subsidiary of Chia Tai Tianqing (CTTQ), for the commercialization of the next-generation TRK inhibitor Eratrectinib in Mainland China.
- Henlius enters into strategic cooperation with Zhejiang Cancer Hospital
On September 30, 2026, Henlius (2696.HK) entered into a strategic cooperation with Zhejiang Cancer Hospital.
- Dizal receives USD 600m upfront payment from AstraZeneca
On September 29, 2026, Dizal Pharmaceutical (688192.SH) announced that it has received a $600 million upfront payment from AstraZeneca (LSE/STO/Nasdaq: AZN).
- GenFleet’s GFH375 granted third Breakthrough Therapy Designation in China
On September 30, 2026, GenFleet Therapeutics (2595.HK) announced that its oral KRAS G12D (ON/OFF) inhibitor, GFH375, has been granted its third Breakthrough Therapy Designation (BTD) by the National Medical Products Administration (NMPA).
- NMPA formally implements the "Pioneer Plan"
On September 29, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"), which took effect on the date of release.
- CSPC’s SYS6052 receives FDA approval for clinical trials in the U.S.
On September 29, 2026, CSPC Pharmaceutical Group Limited (1093.HK) announced that its Class 1 innovative drug, a recombinant herpes zoster vaccine (SYS6052), has received IND approval from the U.S. FDA to initiate clinical trials.
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us